Loading…
HQL
abrdn Life Sciences Investors
NYSE· Financial Services· Asset Management· CUSIP 87911K100
$20.96-2.74%Price as of Aug 29, 18:43 UTC · updated once a day, after the close
Key metrics
- Market cap
- —
- P/E
- 3.2x
- Forward P/E
- —
- P/B
- 1.1x
- Dividend yield
- 10.69%
- Payout
- 33.73%
- EPS
- $6.64
- ROE
- 41.42%
- Profit margin
- 17856.98%
- Revenue growth
- -60.80%
- Beta
- 0.71
- 52-week high
- $22.67
- 52-week low
- $13.88
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -10.8% over 5Y.
today you would have $1,592.87▲ +59.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $16.78 | $13.12 | $13.46 | $14.21 | |
| P/E | 6.0x | 6.0x | 4.3x | 17.0x | — |
| P/S | 5.7x | 5.7x | 4.2x | 15.3x | — |
| P/B | 0.9x | 1.0x | 0.8x | 0.9x | 0.9x |
| EPS | $2.79 |
Fair price, seven ways
Not shown for closed-end funds and BDCs. The methods assume operating profit, and a fund’s earnings per share are capital gains on its portfolio plus interest income — running them through Graham or a discounted cash flow produces a number that looks like a valuation and means nothing. What matters for a fund is its price against net asset value, which this site does not track.
Others in the same sector
Companies of similar size in Financial Services, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| AFJKAimei Health Technology Co., Ltd. | $12.10 | 172.9x | — | — | — | $38.31M |
| AEAQActivate Energy Acquisition Corp. | $10.10 | — | — | — | — | $316.25M |
| AESPAeon Acquisition I Corp. | $9.98 | — | — | — | — | $213.35M |
| APMCAmperCap Acquisition Co | $9.98 |
About the company
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
- Philadelphia, United States
Company description provided by Yahoo Finance.